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Précis 
 
Unter Lucentis® zeigen sich teils sehr unterschiedliche Visusverläufe bei gleicher 
Therapiestrategie. Diese Studie untersuchte die Unterschiede zwischen Patienten mit 
gutem und solchen mit schlechtem Therapieansprechen.
 Abstract (Deutsch) 
 
 
Hintergrund: Die Visusverläufe unter der Therapie mit Ranibizumab (Lucentis®) bei 
neovaskulärer altersbedingter Makuladegeneration (AMD) zeigen ein breites 
Spektrum. Während einige Patienten sehr gut ansprechen und eine Visusverbesserung 
erfahren, zeigen andere deutlich schlechtere Resultate trotz ähnlicher 
Therapieregimes. 
 
Patienten und Methoden: Retrospektive Analyse aller am UniversitätsSpital Zürich 
über mindestens 12 Monate mit Lucentis® behandelten Augen mit neovaskulärer 
AMD. Vergleich der Visusverläufe der 90. (good responders, GR) und 10. Percentile 
(bad responders, BR) nach 3, 12 und 24 Monate und Analyse der demographischen 
Charakteristiken, Läsionstyp und –grösse sowie Anzahl durchschnittliche 
Ranibizumab Injektionen und Kontrollen. Evaluation prädiktiver Faktoren für die 
Zugehörigkeit zu einer der beiden Gruppen.  
 
Ergebnisse: Ein deutlicher Unterschied der Visusverläufe zwischen GR (n=30) und 
BR (n=30) zeigt sich bereits in den ersten 3 Monaten nach Behandlungsbeginn. In GR 
betrug der Visusgewinn 15.7±9 Buchstaben ETDRS nach 3 Monaten, 25.3±7 nach 12 
und 14.0±14 nach 24 Monaten. In BR zeigte sich ein Verlust von 8.3±11 Buchstaben 
ETDRS nach 3 Monaten, 22.1±8 nach 12 und 23.6±13 24 Monate. Erwartungsgemäss 
zeigte sich in den beiden Gruppen einen höheren Anteil an Frauen (64% in BR, 66% 
in GR).  Einzig der Ausgangsvisus war in GR statistisch signifikant schlechter als in 
BR (45.7±10 vs 55.4±11 Buchstaben ETDRS, p<0.05). Weitere signifikante 
Unterschiede fanden sich nicht. Ausgehend von den analysierten Daten konnten keine 
prädiktive Faktoren für die  Gruppenzugehörigkeit (BR/GR) ermittelt werden. 
  
Schlussfolgerungen:  
Allein der Visusverlauf innerhalb der ersten 3 Monate nach Therapiebeginn scheint  
Hinweise für das weitere Ansprechen der intravitrealen Ranibizumab Therapie zu 
liefern. Der Therapieverlauf in den ersten Monaten könnte in Zukunft das 




Background: Treatment of neovascular age related macular degeneration (AMD) with 
Lucentis® shows a broad spectrum regarding the course of visual acuity (VA). While 
some patients show a good response (increase in VA), others disclose much less 
promising results. 
 
Patients and Methods: Retrospective data analysis of all eyes treated for neovascular 
AMD at the University Hospital of Zurich, Switzerland for at least 12 months. 
Comparison of the courses of VA between 90th (good responders, GR) and 10th (bad 
responders, BR) percentiles 3, 12 and 24 months from baseline. Analysis regarding 
demographic data, lesion type and size as well as injection frequency and visits. 
Evaluation of predicitive factors for GR and BR.  
 
Results: Marked difference in the course of VA between GR (n=30) and BR (n=30) is 
already observed 3 months from baseline. In GR the gain in VA after 3, 12 and 24 
was 15.7±9 letters ETDRS, 25.3±7 and 14.0±14. BR showed a deterioration of 8.3±11 
letters ETDRS after 3, 22.1±8 after 12 and 23.6±13 after 24 months. The gender 
distribution was equal with a higher percentage of female patients (64% in BR and 
66% in GR). The baseline VA was statistically significant lower in GR (45.7±10 vs. 
55.4±11, p<0.05) than in BR. No other significant differences in baseline data were 
found, no predictor for group membership could be identified. 
  
Conclusions: Only the course of VA in the first three months seems to be of value for 
an estimation of the response to treatment. In the future the response to treatment in 
the early phase may influence the treatment algorithm and the injection frequency.  
Introduction 
 
Intravitreal injection of Ranibizumab (Lucentis®, Novartis, Basel, Switzerland; 
Genentech Inc., South San Francisco, CA, USA) has rapidly become the standard 
treatment modality for neovascular AMD[1]. It is a Fab fragment of a recombinant 
monoclonal humanized antibody, which inhibits all isoforms of VEGF (vascular 
endothelial growth factor)[2]. Lucentis ® was approved by the FDA (U.S. Food and 
Drug Administration) in 2006 and introduced in Switzerland in January 2007.   
The large clinical trials MARINA[1] and ANCHOR[3], employing monthly 
injections, demonstrated a gain in visual acuity (VA) of 6.6 and 10.7 after 24 months.  
Monthly injections, however, result in both a huge workload and significant costs for 
the healthcare system. Therefore a reduction of the treatment frequency without loss 
of efficacy is desirable. Several studies (PIER[4], EXCITE[5], PrONTO[6], 
SUSTAIN[7], SAILOR Cohort I[8]) tried to address this problem by using different 
individualized treatment regimens.   
 
Despite these trials and the widespread use of Lucentis ®, the ideal injection- and 
monitoring frequency has not been established yet. All studies mentioned above, 
report the course of the average VA among all patients. Naturally, some patients will 
show a better outcome compared to the average, while others show deterioration 
instead of improvement of VA. A retrospective subgroup analysis (unpublished data)   
of the 0.5mg treatment group of the MARINA[1] study revealed that only 161 of the 
231 patients showed a gain in VA. The remaining 70 patients did not achieve any gain 
in VA after 3 months and did also not climb above baseline after the complete 
observation period.  The reason for the different response to treatment remains 
unclear to date.  The aim of this retrospective analysis was to compare the course of 
visual acuity between the 10th (bad responders, BR) and the 90th percentiles (good 
responders, GR) with respect to baseline characteristics (demographic data, lesion 
type and lesion size) and average injections and number of visits and to test whether 





Clinical and demographic data from all patients treated for neovascular AMD at the 
Department of Ophthalmology at the University Hospital of Zurich (University of 
Zurich, Switzerland) starting in June 2006 have been continuously recorded in a 
standardized fashion. For the present retrospective analysis, all patients treated with 
Ranibizumab (Lucentis®) who matched the criteria of the MARINA[1] and 
ANCHOR[3] studies (age ≥50 years, active primary or recurrent neovascular AMD, 
minimally classic, occult or predominantly classic lesion, VA ≥25 and ≤70 letters 
ETDRS, no prior treatment) and had a documented follow-up of 12 or more months 
were selected. Eyes with any pretreatments, such as intravitreal triamcinolone 
acetonide or photodynamic therapy using verteporfin, were excluded. Further 
exclusion criteria were: retinal hemorrhages, endophthalmitis, retinal pigment 
epithelium rips and retinal detachements during the treatment phase.  
 
The course of VA from baseline during an observation period of 24 months of all 
selected eyes was analyzed.  Percentiles of the course of VA were calculated. 
According to the course of VA at month 12, the 10th and 90th percentiles were 
selected as two groups: a bad responder group (BR) and a good responder group 
(GR), respectively. Both groups were analyzed and compared regarding baseline 
characteristics (demographic data, lesion type) as well as the average number of 
injections and follow up visits. 
 
Baseline work-up included dilated funduscopy, color fundus photography, fluorescein 
angiography (FA), optical coherence tomography (OCT) and testing of the visual 
acuity (VA) using EDTRS like LogMAR visual acuity charts[9,10]. Fundus 
photography combined with FA was performed with a digital fundus camera (Zeiss 
FF 450 plus, Carl Zeiss GmbH, Oberkochen, Germany). OCTs were recorded using a 
Stratus OCT (Carl Zeiss GmbH, Oberkochen, Germany) and Spectralis HRT 
(Heidelberg Engineering, Heidelberg, Germany). FA images were analyzed to 
establish the baseline characteristics of the exudative lesions (type and size)[11] using 
a commercial image analysis program (Image Access Enterprise 5, Imagic 
Bildverarbeitungs AG, Glattbrugg Switzerland). Lesion type was defined as 
predominantly classic, minimally classic or occult according to the Macular 
Photocoagulation Study (MPS)[12], Verteporfin in Photodynamic Therapy Study 
(VIP)[13] and Treatment of Age-related Macular Degeneration with Photodynamic 
Therapy Study (TAP)[14,15] Lesion size was defined as the largest diameter of the 
lesion (in millimeters) using a standardized ruler on a standardized screen using the 
30° FA image. Quartiles were calculated for the lesion size, resulting in four groups 
of which the first quartile group comprised of the smallest 25% of all lesion sizes and 
the fourth quartile of the largest 25%. 
 
Follow up examinations only included testing of VA, funduscopy and OCT. FA 
during follow up was only performed if deemed necessary by the treating 
ophthalmologist to preclude active lesions in patients with stable VA and no signs of 
activity (hemorrhage, edema), neither funduscopically nor in OCT.  
 
Treatment algorithm and follow-up scheme of patients analyzed in this study were up 
to the treating ophthalmologist and reflect daily clinical routine that is not based on a 
study protocol. However, a PrONTO-like scheme was basically applied including 2-3 
monthly loading doses at the beginning of the treatment followed by a re-treatment 
phase where the retreatment criteria were: a) vision loss ≥5 letters associated with 
fluid detected by OCT, b) increase in central retinal thickness (≥100µm), c) new onset 
hemorrhage, d) new classic CNV component detected by fluorescein angiography. 
Yet, physicians were not forced to adhere to these guidelines. Hence, the decision for 
treatment or no treatment as well as the time interval to the next appointment was 




For statistical analyses data were imported into a commercially available statistical 
software package (SPSS 13, SPSS Inc., Chicago, Il, USA). Differences in VA 
between both groups at one time-point were analyzed by an unpaired t-test. Deviation 
from normal distribution was tested using the Kolmogorov-Smirnov-test and by 
visual judgment of the histograms. Binary logistic regression was used performed 
using group membership (GR/BR) as dependent variable and age, gender, VA at 
baseline, lesionsize and lesiontype as covariates. 
If not stated otherwise, all values are presented as letters ETDRS mean ± standard 




All data from patients treated with Ranibizumab at our clinic between January 2007 
and July 2009 were analyzed. Out of the data recorded during this period, 491 eyes of 
491 patients met the inclusion criteria and were further analyzed.   
Mean age at study entry was 79.70±7.2 years (79.6±7.2 in female, 79.8±7.1 in male, 
p>0.05); the female to male ratio was approximately 2:1 (326 female, 165 male). 
During this period for the 491 eyes examined, a total of 3750 visits within the first 12 
months after initiation of therapy and a total of 6587 visits within 24 months were 
recorded. A total of 1573 injections within the first 12 months and 2831 injections 
within 24 months were performed. Baseline VA in all eyes included in the study was 
51.59±11.17 letters ETDRS without a statistically significant difference among the  
genders.  Of the 491 lesions examined, 68 were minimally classic, 115 predominantly 
classic and 308 were occult.  
The mean changes in VA of all eyes analyzed are shown on the Figure 1.  Percentile 
calculation at month 12 revealed 30 eyes as GR (good responders) and other 30 eyes 
as BR (bad responders).  The mean gain in VA from baseline in GR was 15.77±9.5 
after 3 months, 25.29±7.2 after 12 months and 14.00±16.0 after 24 months. The mean 
change in VA from baseline in BR was -8.27±11.0 after 3 months, -22.07±8.5 after 12 
months and -23.59±13.6 after 24 months (Figure 2).  
Analysis of demographic and baseline data of the good and bad responders (GR vs. 
BR) did not reveal any statistically significant differences except that patients in GR 
had a statistically significant worse baseline VA than patients in BR (45.97±10.1 vs. 
55.37±11.1, p<0.05). The distribution of the different lesion types among the two 
analyzed groups showed also comparable results. The percentage of occult lesions 
were equal with 57% share in both groups, in GR the remaining fraction showed 16% 
minimally classic and 27% predominantly classic lesions, while in BR the distribution 
was exactly inverted.  
Subgroup analysis of the changes of VA regarding lesion types demonstrated 
comparable responses (Figure 3) and is shown in detail in Table 1.  
 
 
In GR a total of 594 visits (mean±SD 19.8±7.9 )  with 238 Ranibizumab injections 
(7.9±4.9) were documented during the study period of 24 months. In BR a total of 
589 visits (19.6±6.5) had occurred with 226 administrations of Ranibizumab 
(7.5±4.8). There were no statistically differences between GR and BR with respect to 
visiting and injection frequency. 
Conclusions 
 
Except for the  lower baseline VA in the GR group, there were neither significant 
differences at baseline between both groups, nor were we able to identify a single or a 
group of baseline variables that could predict the course of VA towards GR or BR. 
Nevertheless, we found that the response already within the first three months is 
significantly different between both groups.  
Good responders showed a statistically significant lower baseline VA. Possibly in the 
GR group the onset of the disease is perceived earlier and as a more rapid 
deterioration of visual acuity, hence probably leading to a prompt initiation of 
treatment at a stage of disease with greater recovery potential and therefore bigger 
gain in VA as compared to the BR group. Yet, since time between symptoms and an 
eventual treatment was not measured, this point remains speculative. 
It can be argued that patients with a rather high VA at initiation of therapy may have a 
greater chance to loose than to gain VA (as they already may have a high level of VA) 
and vice versa: patients may have a greater chance to improve their visual acuity 
when starting from a rather low VA – thus affecting the outcome.  
The second, very interesting result is that the course of BR and GR is very different 
already 1 month after start of therapy. This finding is in conjunction with the results 
of a subgroup analysis of the MARINA trial, where two groups of patients were 
classified: initial responders (n=161) and initial non-responders (n=70). The group of 
initial responders showed a similar course like the patients of the GR of our study, 
i.e., a gain of more than 10 letters (average) at 3 months from baseline. In contrast to 
this, the group of BR from the study presented show a significantly different course in 
VA as compared to the initial non-responders from the MARINA subanalysis. While 
patients from the BR group lost more than 20 letters (on average) at 12 months, the 
initial non-responders from the MARINA[1] study had only a loss of 2.5 letters 
ETDRS compared to baseline. This rather clinically stable course, that is still much 
more favourable than the natural course of the disease, made the authors ask 
themselves critically, if the bad responders should be given a different treatment 
regimen such as a greater dosage of compound or more frequent injections. Since the 
injection and visit frequency in BR was very much the same as in the GR, yet still 
being much lower than in the MARINA with monthly injections, raises concerns 
about a possible undertreatment of patients in BR. On the other hand, differences in 
the patient population of our study compared to the MARINA subanalysis population 
(different gender distribution, different lesion types within the initial non-responder 
group etc) may account for the obvious differences. Since the full data of this 
subgroup analysis of MARINA was not available, this point remains speculative. 
Besides this, other factors, such as genetic background, are still evaluated for their 
influence on disease development and response to treatment. Observing that patients 
may show a dramatic decline in VA despite intensive treatment raises the question 
whether to stop the anti-VEGF treatment in these cases or: Is continuing the treatment 
in BR reasonable, considering the high socioeconomic costs without evident clinical 
benefit? Since to date no prediction for a good or bad outcome (gain of VA) can be 
made prior to therapy, the decision to stop treatment is guided rather by the needs of 
the patient and the ophthalmologist’s perception of the development of the condition.   
 
In conclusion, the authors suggest to closely monitor the course of VA development 
after initiation of anti-VEGF treatment. Further studies are warranted to test whether 
the initial response to treatment within the first three months is of predictive value for 
GR or BR. Taken into account the differences of the BR and the subpopulation of the 
MARINA study, a more frequent follow up and possibly higher injection frequency in 
patients not showing a great initial improvement within the first three months, should 
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Figure 1. Visual acuity in letters ETDRS during the observation period of 24 months 
after start of treatment. Dots mark the mean, whiskers the ± 1 standard error of the 
mean interval (SEM). Course of visual acuity in all patients included in the study.  
 
Figure 2.  Visual acuity in letters ETDRS during the observation period of 24 months 
after start of treatment per percentile group: circles denote the 10th percentile, squares 
denote the 90th percentile. Mean (squares and circles), whiskers the ± 1SEM interval.  
 
Figure 3. Visual acuity in letters during the observation period of 24 months after 
start of treatment per percentile group (squares denote the 10th percentile, circles 
denote the 90th percentile) and subdivided for the three different lesion types. Mean 
(squares and circles), whiskers the ± 1SEM interval. 
 
Table 1. Baseline VA (0) and follow-up VA in letters ETDRS after 3, 12 and 24 
months subdivided for the three different lesion types. VA is shown as the mean ± 
standard deviation. 
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